Updates from the SECURE-IBD Database
Surveillance Epidemiology of Coronavirus under Research Exclusion (SECURE-IBD) is an international registry of pediatric and adult IBD patients who develop COVID-19. More information can be found at www.covidibd.org.
What does SECURE-IBD data tell us about the experiences of children and adolescents with IBD and COVID19?
The majority of children and adolescents reported to registry had a mild course of COVID-19, with the vast majority requiring outpatient (non-hospital) care only. There have been no pediatric patients reported to the SECURE-IBD registry who required a ventilator, required intensive care, or who passed away.
What does SECURE-IBD data tell us about TNF-antagonist medications and COVID-19?
TNF-antagonist medications (including infliximab [Remicade®] and adalimumab [Humira®]) by themselves do not appear to be associated with severe COVID-19 outcomes such as hospitalization or death. This information suggests that patients are safe to continue these medications during the COVID-19 pandemic. More information is needed to determine whether patients on combination therapy (e.g. a TNF-antagonist medication with another medication such as methotrexate, azathioprine, or 6-mercaptopurine) are at increased risk of severe COVID-19 outcomes.
What does SECURE-IBD data tell us about corticosteroids and COVID-19?
In adults, corticosteroids (such as prednisone and prednisolone) are associated with severe COVID-19 outcomes. However, this trend has not been seen in children. Patients and families should work with their IBD doctor to weigh the risks versus benefits of using steroids during the COVID-19 pandemic.